W.R. Berkley (WRB) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Good day, and welcome to W. R. Berkley Corporation's First Quarter 2025 Earnings Conference Call. Today's conference call is being recorded. The speakers’ remarks may contain forward-looking ...

The Sherwin-Williams Company excels in profitability and dividends but is overvalued. Read more on my earnings preview and a ...

An Alabama lawmaker makes false connection between undocumented immigrants and public "safety" to justify a bill that would ...

In its upcoming report, Ryder (R) is predicted by Wall Street analysts to post quarterly earnings of $2.40 per share, reflecting an increase of 12.2% compared to the same period last year. Revenues ...

In the popular r/Economy subreddit, the user said they sold all of their holdings and are “100% cash until 2026 midterms ...

Beyond analysts' top -and-bottom-line estimates for D.R. Horton (DHI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the ...

A senior at Villa Maria Academy, Manasvi Koneru is President of the school’s Diversity, Equity, Inclusion and Belonging Club, was a Villa Maria Social Justice Day Presenter on Physical ...

After the collective decline of commodities on the first day post-holiday, the downward trend of SHFE zinc, which resumed at the end of March, has come to a halt. Recently, the futures price has been ...